Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

A Look Inside the Advocate Experience at Advocates for Arthritis

Eric Dein, MD  |  

Eric Dein, MD, shared rheumatology perspectives with five congressional offices on Sept. 28 as part of the virtual Hill Day. Read his hour-by-hour account, including staffer education, legislative requests and prior authorization woes.

Guselkumab Promising in Patients with PsA

  |  

Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).

Live Varicella Zoster Vaccine Safe, Effective with TNF Inhibitors

Lisa Rapaport  |  

(Reuters Health)—Adults 50 years and older who take tumor necrosis factor inhibitors (TNFi’s) for a range of inflammatory disorders can receive effective protection from shingles with a live varicella zoster vaccine, a clinical trial suggests.1 Researchers randomized 617 participants receiving TNFi’s in a 1:1 ratio to receive either the Zostavax live varicella zoster vaccine or…

Severe COVID-19 May Trigger Autoimmunity

Reuters Staff  |  

Reuters)—Severe COVID-19 may trick the immune system into producing autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications.1 They found autoantibodies in blood samples from roughly 50% of the 147 COVID-19 patients they studied, but in fewer than 15% of 41…

The Role of ANA Positivity in Patients with RA

  |  

Recent research suggests patients with RA and a positive test for anti-nuclear antibody (ANA) may not have a different disease course than patients with RA who test negative for ANA. However, these patients may experience different treatment courses.

Nonserious Infection Rates with Biologics Used to Treat RA

  |  

Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large.